Labigat (Ranolazine)

Ranolazine is an anti‑anginal agent used in the management of coronary artery disease‑related chest pain.

• Chronic stable angina: improves exercise tolerance and reduces frequency of angina episodes.
• Refractory angina: provides additional symptom relief when conventional therapy is insufficient.
• Ischemic heart disease: helps to alleviate myocardial ischemia and associated discomfort.

• Ranolazine selectively inhibits the late inward sodium current in cardiac myocytes, which reduces intracellular sodium accumulation. This secondary effect lowers calcium overload within the cells, improving myocardial relaxation, enhancing coronary blood flow, and decreasing myocardial oxygen demand, thereby alleviating angina symptoms.

Ranolazine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Nausea: feeling of queasiness or urge to vomit.
• Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects

• QT interval prolongation: may increase risk of cardiac arrhythmias.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Liver injury: elevated liver enzymes or jaundice.
• Cardiac arrhythmia: irregular heart rhythm requiring medical attention.

Before initiating therapy with Ranolazine, several safety considerations should be observed.

• ECG monitoring: assess QT interval and baseline cardiac rhythm.
• Renal function assessment: adjust dose in patients with impaired kidney function.
• Hepatic impairment caution: avoid or use with caution in severe liver disease.
• Concomitant QT‑prolonging drugs: avoid combining with other agents that lengthen QT interval.
• Pregnancy and lactation: evaluate risk‑benefit ratio before use.
• Store at below 25°C: keep in the original pack, protect from moisture.

Ranolazine can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): may increase Ranolazine levels.
• Strong CYP3A inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Other QT‑prolonging agents (e.g., sotalol, amiodarone): heighten risk of arrhythmia.

Moderate Interactions (Monitor Closely)

• Digoxin: may increase serum concentrations.
• Warfarin: potential alteration of anticoagulant effect.
• Calcium channel blockers (e.g., diltiazem, verapamil): may raise Ranolazine exposure.
• Beta‑blockers: additive anti‑anginal effect, monitor blood pressure.
• Statins (e.g., simvastatin): possible increase in statin levels.